Rescue Medication

Phase 3

Rescue Medication is one of 232 therapeutic programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

231

Competitors

Pipeline

Status by Indication[2][1]

Indication

Esophageal Squamous Cell CarcinomaRecruiting

Lung NeoplasmRecruiting

Non-Small Cell Lung CancerRecruiting

Colorectal CancerRecruiting

Prostate CancerRecruiting

Bladder CancerRecruiting

Diffuse Large B-Cell LymphomaRecruiting

Non Muscle Invasive Bladder CancerRecruiting

Breast NeoplasmsRecruiting

Oesophageal Squamous Cell CarcinomaRecruiting

Esophageal Squamous Cell CarcinomaPreclinical

Recruiting

Lung NeoplasmPhase 2

Recruiting

Non-Small Cell Lung CancerPhase 3

Recruiting

Colorectal CancerPreclinical

Recruiting

Prostate CancerPhase 3

Recruiting

Bladder CancerPreclinical

Recruiting

Diffuse Large B-Cell LymphomaPhase 3

Recruiting

Non Muscle Invasive Bladder CancerPreclinical

Recruiting

Breast NeoplasmsPhase 3

Recruiting

Oesophageal Squamous Cell CarcinomaPreclinical

Recruiting

Showing 10 of 14 indications

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Rescue Medication

Merck & Co.

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

Gemzar

GGynecologic Oncology Group

Preclinical

72 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Treatment

GSK

Preclinical

1 10

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Not yet recruiting

Study completion

NCT07697625

Q2 2028

PreclinicalRecruiting

Oesophageal Squamous Cell Carcinoma

NCT07405151

Q1 2029

PreclinicalRecruiting

Non Muscle Invasive Bladder Cancer

NCT06637423

PreclinicalRecruiting

Ovarian Cancer Recurrent

NCT06843447

Q4 2029

PreclinicalRecruiting

Colorectal Cancer

NCT06428409

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06925737·1,440 enrolled

Diffuse Large B-Cell Lymphoma1 trial

A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06717347·1,046 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06843447·460 enrolled

Lymphoma, Large B-Cell, Diffuse1 trial

A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06890884·594 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780098·144 enrolled

10 more indications

Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06966700·2,400 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06312137·780 enrolled

Non Muscle Invasive Bladder Cancer1 trial

A Phase 1/2 Open-label Clinical Study to Evaluate the Safety and Efficacy of Intravesical Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (NMIBC)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06637423·32 enrolled

Oesophageal Squamous Cell Carcinoma1 trial

A Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06F

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07405151·60 enrolled

Triple Negative Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06841354·1,000 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780111·298 enrolled

Castration Resistant Prostatic Cancer1 trial

MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06863272·360 enrolled

Colorectal Cancer1 trial

A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06428409·220 enrolled

Bladder Cancer1 trial

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07232602·55 enrolled

Unspecified1 trial

A Clinical Study to Evaluate the Plasma Pharmacokinetics of a Single Dose of MK-4082 With and Without Diltiazem Coadministration in Healthy Participants

Not yet recruiting· Merck & Co. logo

Merck & Co.·Phase 1·NCT07697625·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 15 trial records for Rescue Medication. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rescue Medication. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Merck & Co.

Rescue Medication

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q2 2028

Q1 2029

Q4 2029

Trials by Indication[1]

Prostate Cancer1 trial

Diffuse Large B-Cell Lymphoma1 trial

Ovarian Cancer Recurrent1 trial

Lymphoma, Large B-Cell, Diffuse1 trial

Lung Neoplasm1 trial

Breast Neoplasms1 trial

Non-Small Cell Lung Cancer1 trial

Non Muscle Invasive Bladder Cancer1 trial

Oesophageal Squamous Cell Carcinoma1 trial

Triple Negative Breast Neoplasms1 trial

Esophageal Squamous Cell Carcinoma1 trial

Castration Resistant Prostatic Cancer1 trial

Colorectal Cancer1 trial

Bladder Cancer1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News